We use cookies to help provide you with the best possible online experience. Learn more

Press releases

RaySearch’s CEO sells shares – remains long-term shareholder

PDF

RaySearch’s founder and CEO, Johan Löf, has sold 200,000 Class B shares in RaySearch Laboratories AB during the period 27-30 August 2019. Johan Löf remains a long-term shareholder of RaySearch. After the transaction, Johan Löf owns 6,243,084 Class A shares and 418,393 Class B shares, corresponding to 19.4 percent of the total number of shares and 56.9 percent of the total number of votes in the company.

“Due to private financial reasons, I have decided to sell a small portion of my holding in RaySearch. I have not sold any shares in RaySearch since 2013 and this transaction corresponds to less than 3 percent of my total holding in RaySearch. I remain committed with continued strong confidence in RaySearch’s future. We have many exciting opportunities ahead of us and I look forward to leading and developing RaySearch towards our strategic goals,” says Johan Löf, RaySearch’s founder and CEO.

The transaction has been reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations. 

For further information, please contact:

Johan Löf, Presidentand CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com 

Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com 

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

More information about RaySearch is available at www.raysearchlabs.com 

* Subject to regulatory clearance in some markets.

PDF